Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations

Key takeaways from a recent study of tipifarnib as treatment for recurrent and/or metastatic mHRAS head and neck squamous cell carcinoma.

EP. 1: Presentation: Tipifarnib in HNSCC With HRAS Mutations

October 15th 2021

Drs Cesar Perez and Victoria Meucci Villaflor review “Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations” by Ho AL, et al.

EP. 2: Precision Medicine in Head and Neck Cancer

October 22nd 2021

Key takeaways from a paper that evaluated the efficacy of tipifarnib in recurrent and/or metastatic mHRAS head and neck squamous cell carcinoma.

EP. 3: HRAS Mutations in Head and Neck Cancer

October 29th 2021

The significance of studying strategies that target HRAS mutations in head and neck squamous cell carcinoma.

EP. 4: Tipifarnib in mHRAS HNSCC: Remaining Questions

November 5th 2021

Drs Cesar Perez and Victoria Meucci Villaflor consider questions raised by a recent study of tipifarnib in head and neck squamous cell carcinoma.

EP. 5: HNSCC: Integrating Tipifarnib Into Treatment Algorithms

November 12th 2021

Potential implications of ongoing studies evaluating tipifarnib for patients with HRAS-mutated head and neck squamous cell carcinoma.

EP. 6: Experts Examine Tipifarnib to Treat HNSCC With HRAS Mutations

November 15th 2021

Cesar A. Perez, MD, and Victoria M. Villaflor, MD, discuss tipifarnib in patients with head and neck cancers harboring HRAS mutations.

EP. 7: Improving the Management of HNSCC: Next Steps

November 16th 2021

Dr Cesar Perez reacts to the utilization of next-generation sequencing in head and neck squamous cell carcinoma and highlights future areas of study.